Progression of HIV in haemophilia

Haemophilia

Volumn 4, Issue 4, 1998, Pages 601-609

  Ragni, M V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; AIDS progression; CD4; Haemophilia; HIV infection; HIV RNA

Indexed keywords

ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR CONCENTRATE; CD4 ANTIGEN; CHEMOKINE RECEPTOR; NEUTRALIZING ANTIBODY; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; ANTIBODY TITER; B LYMPHOCYTE; BLEEDING; BLEEDING TENDENCY; CAUSE OF DEATH; CHRONIC LIVER DISEASE; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HEMOPHILIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LIFE CYCLE; LIVER TOXICITY; LONG TERM CARE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 0031876135     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440601.x     Document Type: Conference Paper

References (63)

1. Ragni MV, Winkelstein A, Kingsley LA, Spero JA, Lewis JH. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with haemophilia A and B. Blood 1987; 70: 786-90.
2. Ragni MV, Kingsley LA. Cumulative risk for AIDS and other HIV outcomes in a cohort of haemophiliacs in Western Pennsylvania. J Acq Immunodef Syndr 1990; 3: 708-13.
3. Ragni MV, Belle SH, Jaffee RH, Locker J, Duerstein SL, Bass DC, et al. Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with haemophilia. Blood 1993; 81: 1889-97.
4. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
5. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373; 123-6.
6. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
7. Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in haemophiliacs. J Acq Immunodef Syndr 1998; in press.
8. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services (DHHS), Bethesda, MD, November, 1997.
9. O'Brien TR, Blattner WA, Waters D, Eyster ME, Hilgartner MW, Cohen AR, et al. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter haemophilia cohort study. JAMA 1996; 276: 105-10.
10. Ehmann WC, Eyster ME, Wilson SE, Andes WA, Goedert JJ. Relationship of CD4 lymphocyte counts to survival in a cohort of haemophiliacs infected with HIV. J Acq Immunodef Syndr 1994; 7: 1095-8.
11. + lymphocytes as prognostic markers of HTV-1 infection. Ann Intern Med 1997; 126: 946-54.
12. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997; 126: 929-38.
13. + lymphocyte counts predict both response to antiretroviral therapy and failure. Ann Intern Med 1997; 126: 939-45.
14. Markowitz M, Saag M, Powderly WG, Jurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HTV-1 protease, to treat HIV-1 infection. N Engl J Med 1996; 333:1534-9.
15. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
16. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
17. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-6.
18. Denning D, Michelet C, Jouan M, Baril L, Goguel J, Torriani F, et al. Impact of highly active antiretroviral therapy (HAART) on opportunistic infections. In Highlights from the 37th ICAAC: Focus on HIV disease and AIDS. Infect Med 1997; 14 (Suppl B): 29-30.
19. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-5.
20. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
21. + T cell responses associated with control of viremia. Science 1997; 278: 1447-50.
22. Jason J, Lui KJ, Ragni MV, Darrow WW, Hessol N. Risk of developing AIDS in HIV-infected cohorts of haemophiliac and homosexual men. JAMA 1989; 261: 725-7.
23. Rosenberg PS, Goedert JJ, Biggar RJ. Effect of age at seroconversion on the natural AIDS incubation distribution. AIDS 1994; 8: 803-10.
24. Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. J Infec Dis 1995; 172: 648-55.
25. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 1573-9.
26. Phillips AN, Sabin CA, Elford J, Bofill M, Timms A, Janossy G, Lee CA. Serum beta 2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup. J Acq Immunodefic Syndr 1996; 13: 262-6.
27. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi J. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 166-72.
28. Choi S, Lagakos SW, Schooley RS, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical disease progression in persons with aymptomatic HIV infection taking zidovudine. Ann Intern Med 1993; 118: 674-80.
29. Ragni MV, Kingsley LA. Comparative studies of CD4 and viral markers between haemophiliacs and gay men before and at the time of AIDS diagnosis. Thromb Haemost 1995; 73: 1458 (#2133) (abstract).
30. Ragni MV, Amato DA, LoFaro ML, deGruttola V, van der Horst C, Eyster ME, et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in haemophiliac and nonhaemophiliac subjects with asymptomatic human immunodeficiency virus-1 infection. Blood 1995; 85: 2337-46.
31. Kissler S, Susal C, Opelz G. Anti-MP-1 alpha and anti-RANTES antibodies: new allies of HIV-1? Clin Immunol Immunopath 1997; 84: 338-41.
32. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HTV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273; 1856-62.
33. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997; 277: 959-65.
34. Vincenzi E, Bagnarelli P, Santagostino E, Ghezzi S, Alfano M, Sinnone MS, et al. Haemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood 1997; 89: 191-200.
35. Kirchoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995; 332: 228-332.
36. Mariani R, Kirchoff F, Greenough TC, Sullivan JL, Desrosiers, Skowronski J. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol 1996; 70: 7752-64.
37. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337: 1267-74.
38. Sabin CA, Bofill M, Phillips AN, Elford J, Janossy G, Lee CA. Relation between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with haemophilia. J Acq Immunodef Syndr 1997; 16: 279-83.
39. de Bracco MM, Felippo M, Vernava D, Perez-Bianco R, de Tezanos Pinto M. Nitric oxide production and disease evolution in HIV-infected haemophilic patients. AIDS 1997; 11: 822-4 (letter).
40. Jason J, Sleeper LA, Donfield SM, Murphy J, Warrier I, Arkin S, Evatt B. Evidence for a shift from a type 1 lymphocyte pattern with HIV disease progession. J Acq Immunodef Syndr 1995; 10: 471-6.
41. Kaufman RF, Gertner JM, Sleeper LA, Donfield SM. Growth hormone secretion in HIV-positive versus HIV-negative haemophilic males with abnormal growth and pubertal development. J Acq Immunodef Syndr 1997; 15: 137-44.
42. Yamanaka T, Fujimura Y, Ishimoto S, Yoshioka A, Konishi M, Narita N, et al. Correlation of titer of antibody to principal neutralizing domain of HIVMN strain with disease progression in Japanese haemophiliacs seropositive for HIV type 1. AIDS Res Hum Retroviruses 1997; 13: 317-26.
43. Eyster ME, Fried MW, DiBisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in haemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84: 1010-3.
44. Ragni MV, Faruki H. HCV RNA in haemophiliacs with AIDS and AIDS-associated lymphoma. Liver Disease in Hemophilia Conference, Atlanta, 1995, P3.
45. Picchio GR, Nakatsuno M, Boggiano C, Sabbe R, Corti M, Daruich J, et al. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean haemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co-infection. J Med Virol 1997; 52: 219-25.
46. Chambost H, Gerolami V, Halfon P, Thuret I, Michel G, Sicardi F, et al. Persistent hepatitis C virus RNA replication in haemophiliacs: role of co-infection with human immunodeficiency virus. Br J Haematol 1995; 91: 703-7.
47. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect of human immunodeficiency virus infection on hepatitis C virus infection in haemophiliacs. Dig Dis Sci 1996; 41: 1265-72.
48. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of haemophilic men. J Infec Dis 1997; 175: 164-8.
49. Pasi KJ, Evans JA, Wadhwa M, Thorpe R, Hill FG. Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood-borne virus infection. Br J Haematol 1995; 91: 191-6.
50. Weimer R, Zipperle S, Daniel V, Opelz G. In vitro cytokine treatment of B cell defects in HIV-infected haemophilia patients. Vox Sang 1995; 69: 27-37.
51. Schogl D, Zimmerman K, Turecek PL, Schwarz HP, Eibl MM, Mannhalter JW. Effect of high- versus intermediate-purity blood coagulation factor concentrates on HIV-I replication. Vox Sang 1996; 70: 195-7.
52. Ragni MV, Ruben RL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody response to immunization in patients with haemophilia with and without evidence of HTLV-III infection. J Lab Clin Med 1987; 109: 545-9.
53. Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-β as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in haemophiliacs. Blood 1994; 84: 2021-30.
54. Deitcher SR, Tuller J, Dugdale M. Effect of intermediate-and high-purity factor VIII concentrates on immune function in HIV-seropositive haemophiliacs as assessed by quantitative CD4 counts. Haemophilia 1997; 3: 265-9.
55. Astermark J, Johns son H, Stigendal L, Lethagen S, Berntorp E. HIV-disease progression in Swedish haemophiliacs and the influence of replacement therapy. Haemophilia 1997; 3: 277-82.
56. Goedert JJ, Cohen AR, Kessler CM, Eichinger S, Seremetis SV, Rabkin CS, et al. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Lancet 1994; 344: 1238.
57. Ragni M. Protease inhibitor antiretroviral therapy increases ALT and HCV RNA in chronically-transfused patients with haemophilia. Blood 1997; 90: 158a (abstract).
58. Ragni MV, Bontempo FA, Myers DJ, Oral A, Kiss JE. Hemorrhagic sequelae of immune thrombocytopenic purpura (ITP) in HIV-infected haemophiliacs. Blood 1990; 75: 1267-70.
59. Evatt BL. CDC Report on bleeding complications observed among persons with haemophilia treated with protease inhibitors. Centers for Disease Control, Atlanta, 1996.
60. Ginsburg C, Salmon-Ceron D, Vassilief D, Rabian C, Rotschild C, Fontenay-Roupie M, et al. Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS 1997; 11: 388-9.
61. Helal A. HIV protease inhibitors and increased bleeding in haemophilia? Can Med Assoc J 1997; 156: 90.
62. Yee TT, Amrolia PJ, Lee CA, Mir N, Giangrande PL. Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 1997; 3: 220-1.
63. Ragni MV, Weissfeld JL. Model of the impact of HIV infection on the size of future haemophilia and carrier birth cohorts. J Acq Immunodef Syndr 1996; 13: 160-8.